605077 Zhejiang Huakang Pharmaceutical
- 23.36
- +0.19+0.82%
Zhejiang Huakang Pharmaceutical News
Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) 7.7% Gain Last Week Benefited Both Retail Investors Who Own 43% as Well as Insiders
Key Insights The considerable ownership by retail investors in Zhejiang Huakang Pharmaceutical indicates that they collectively have a greater say in management and business strategy The top 12 shar
Express News | Huafu Securities: There may be more room for alternatives to natural sweeteners in the future
Huakang Co., Ltd. (605077): Sugar alcohol sales are growing steadily, and production capacity in Zhoushan is about to be released
Incident: Huakang Co., Ltd. released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 2.78 billion yuan, +26.5% year over year; net profit to mother was 370 million yuan, +16.3% year over year. 2024Q1 single
Huakang Co., Ltd. (605077.SH) announced first-quarter results. Net profit of 79.986 million yuan decreased 11.15% year over year
Huakang Co., Ltd. (605077.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved operating income of 6...
Insufficient Growth At Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077) Hampers Share Price
Zhejiang Huakang Pharmaceutical Co., Ltd.'s (SHSE:605077) price-to-earnings (or "P/E") ratio of 13.7x might make it look like a strong buy right now compared to the market in China, where around half
Huakang Co., Ltd. (605077) Comment: The annual results are in line with expectations, the 23Q4 single quarter revenue reached a record high, and the Zhoushan project progressed in an orderly manner to start new growth
The company released its 2023 annual report, and the results were in line with expectations: during the reporting period, the company achieved revenue of 2,783 billion yuan (YoY +26%), net profit attributable to mother of 371 million yuan (YoY +16%), net profit not attributable to mother of 3.5 million yuan.
Huakang Co., Ltd. (605077): Baizhuodou will not stop, wind and rain will not change Ling Yunzhi
Key investment points The 2023 company achieved revenue of 2,783 billion yuan, up 26% year on year, in line with expectations 1) Looking at the whole year, the 2023 company achieved revenue of 2,783 billion yuan, an increase of 26% year on year, and achieved net profit to mother 3.
Huakang Co., Ltd. (605077.SH): Net profit in 2023 increased 16.34% year-on-year, and plans to transfer 10 to 3 to 7 yuan
Gelonghui, April 18 | Huakang Co., Ltd. (605077.SH) announced its 2023 annual report. Operating revenue for the reporting period was 2,783 billion yuan, up 26.48% year on year; net profit attributable to shareholders of listed companies was 371 million yuan, up 16.34% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 357 million yuan, up 12.26% year on year; basic earnings per share were 1.63 yuan. The company plans to distribute a cash dividend of 7 yuan (tax included) to all shareholders for every 10 shares, and plans to transfer 3 shares to all shareholders for every 10 shares in a capital reserve fund.
Express News | Huakang Co., Ltd. plans to invest in the construction of an industrialization project for the comprehensive utilization of hemicellulose resources
Huakang Co., Ltd. (605077.SH): The possibility that the company will build overseas factories in the future is not ruled out
Gelonghui, March 12 | Huakang Co., Ltd. (605077.SH) recently said during a survey receiving institutional investors that there are currently no plans for large-scale expansion of the Kaihua plant area, and that the company is investing in the construction of a “1 million ton corn deep-processed health food ingredient project” in the Zhoushan International Grain and Oil Industrial Park in Zhejiang Province. The project has an investment amount of 2,479 billion yuan. The construction period is 5 years. The first phase of construction is 2 years, mainly liquid syrup, liquid sugar alcohol and some crystalline sugar alcohol products; the second phase of construction is 3 years, and new product lines such as dietary fiber and modified starch will be put into construction one after another. Not ruled out
Huakang Co., Ltd. (605077.SH): Falling corn prices will have a positive impact on business performance
Gelonghui, March 12 | Huakang Co., Ltd. (605077.SH) recently said during a survey reception from institutional investors that corn starch is one of the main raw materials required for production, and the company generally guarantees an inventory of 1-2 months of use. At the same time, in response to fluctuations in the price of corn starch, the company will also do some hedging. The company's business performance is affected by various factors such as industry development, market supply and demand conditions, and changes in product sales prices. The decline in corn prices will have a certain positive impact on the company's business performance.
Declining Stock and Solid Fundamentals: Is The Market Wrong About Zhejiang Huakang Pharmaceutical Co., Ltd. (SHSE:605077)?
With its stock down 9.8% over the past three months, it is easy to disregard Zhejiang Huakang Pharmaceutical (SHSE:605077). But if you pay close attention, you might gather that its strong financial
Huakang Co., Ltd. (605077.SH) will list and circulate approximately 76.2697 million restricted shares on February 19
Huakang Co., Ltd. (605077.SH) announced that the restricted shares currently listed and circulated are the company's initial public offering...
Zhejiang Huakang Pharmaceutical (SHSE:605077) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Huaan Securities: The new functional sugar substitute market is expected to bring investment opportunities in the industrial chain from 0-1
The process of the new functional sugar substitute market from 0-1 is expected to bring investment opportunities in the industrial chain.
Huakang Co., Ltd. (605077.SH): The subsidiary plans to acquire 100% of Jinggong Agriculture's shares held by Huijishan for 93.0615 million yuan
Gelonghui, January 19 | Huakang Co., Ltd. (605077.SH) announced that its wholly-owned subsidiary Zhoushan Huakang Biotechnology Co., Ltd. intends to acquire 100% of the shares of Zhejiang Jinggong Agricultural Development Co., Ltd. (“Huijishan”) held by Huijishan Shaoxing Liquor Co., Ltd. (“Huijishan”) for RMB 93.0615 million. After the acquisition is completed, Jinggong Agriculture will be included in the scope of the company's consolidated statements. The transaction is based on a decision made by the listed company's business development needs. Jinggong Agriculture is adjacent to Zhoushan Huakang. Through this acquisition of Zhoushan Huakang, it has obtained an area of 37,397.00 square meters
Huakang Co., Ltd. (605077.SH): There are currently no plans for large-scale expansion of the Kaihua plant
Gelonghui, January 16丨Huakang Co., Ltd. (605077.SH) said on the investor interactive platform that there are currently no plans for large-scale expansion of the Kaihua factory area. The company is investing in the construction of a “1 million ton corn deep-processed health food ingredients project” in the Zhoushan International Grain and Oil Industrial Park in Zhejiang Province. The project has an investment amount of 2,479 billion yuan. The construction period is 5 years. The first phase of construction is 2 years, mainly liquid syrups and some crystalline sugar alcohol products; the second phase of construction is 3 years, and new product lines such as dietary fiber and modified starch will be put into construction one after another.
“Huakang Shares (605077.SH): Huakang Convertible Bonds” will be listed for trading on January 15
Huakang Co., Ltd. (605077.SH) announced that the company's 1.03 billion yuan convertible corporate bonds will be 202...
Huakang Co., Ltd. plans to increase capital to subsidiaries by 700 million yuan to implement fund-raising projects
Gelonghui, January 3 | Huakang Co., Ltd. announced in the evening that the company plans to use the capital raised to increase the capital of its wholly-owned subsidiary Zhoushan Huakang Biotechnology Co., Ltd. (“Zhoushan Huakang”) by 700 million yuan to implement the fund-raising project “1 Million Tons of Corn Deeply Processed Health Food Ingredients Project”. After the capital increase was completed, Zhoushan Huakang's registered capital increased to 1 billion yuan, and the company still holds 100% of Zhoushan Huakang's shares.
Huakang Co., Ltd. (605077.SH): Plans to increase the capital of Zhoushan Huakang by 700 million yuan to implement the fund-raising project “1 Million Tons of Corn Deep Processing Health Food Ingredients Project”
Gelonghui, January 3 | Huakang Co., Ltd. (605077.SH) announced that in order to ensure the smooth implementation of the “1 Million Tons of Corn Deep Processed Health Food Ingredients Project”, the company held the 11th meeting of the 6th board of directors and the 10th meeting of the 6th board of supervisors to review and pass the “Proposal on Using Raised Capital to Increase the Capital of Wholly-owned Subsidiaries”, and decided to increase the capital of Zhoushan Huakang by RMB 700 million to implement the fund-raising project “1 million tons of corn deeply processed health food ingredients project”.
Analysis
Price Target
No Data
